Januvia price-listed and set for launch in Japan
07 December 2009
Ian Haydock
Please Login to read the full article.
07 December 2009
Ian Haydock
Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) has received a reimbursement price in Japan, clearing the way for its launch as the first drug in its class in the country once it is included in the tariff on December 11th.
The once-daily product was filed in Japan in late 2007...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Mitsubishi Tanabe's DPP-4 inhibitor teneligliptin filed in first market
- Three month review delay in US sets Takeda's alogliptin further back in diabetes
- EC approval for BI/Lilly's one-dosage Trajenta for type 2 diabetes
- EU's CHMP positive on Boehringer and Lilly's linagliptin
ANALYSIS
COMMENT
Other Informa Comment
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
